683 related articles for article (PubMed ID: 16952434)
1. Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IB-IIA cervical cancer.
Behtash N; Nazari Z; Ayatollahi H; Modarres M; Ghaemmaghami F; Mousavi A
Eur J Surg Oncol; 2006 Dec; 32(10):1226-30. PubMed ID: 16952434
[TBL] [Abstract][Full Text] [Related]
2. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group.
Eddy GL; Bundy BN; Creasman WT; Spirtos NM; Mannel RS; Hannigan E; O'Connor D
Gynecol Oncol; 2007 Aug; 106(2):362-9. PubMed ID: 17493669
[TBL] [Abstract][Full Text] [Related]
3. Ten-year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy.
Hwang YY; Moon H; Cho SH; Kim KT; Moon YJ; Kim SR; Kim DS
Gynecol Oncol; 2001 Jul; 82(1):88-93. PubMed ID: 11426967
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study.
Eddy GL; Manetta A; Alvarez RD; Williams L; Creasman WT
Gynecol Oncol; 1995 Jun; 57(3):412-6. PubMed ID: 7774847
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy followed by radical surgery and radiotherapy vs. pelvic irradiation in patients with cervical cancer FIGO stage IIB - IVA.
Kornovski Y; Gorchev G
J BUON; 2006; 11(3):291-7. PubMed ID: 17309152
[TBL] [Abstract][Full Text] [Related]
6. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy.
Tsai CS; Lai CH; Wang CC; Chang JT; Chang TC; Tseng CJ; Hong JH
Gynecol Oncol; 1999 Dec; 75(3):328-33. PubMed ID: 10600284
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of bulky stage IB and IA cervical cancer patients treated by radical hysterectomy with and without neoadjuvant chemotherapy: long-term follow-up.
Manusirivithaya S; Chareoniam V; Pantusart A; Isariyodom P; Srisomboon J
J Med Assoc Thai; 2001 Nov; 84(11):1550-7. PubMed ID: 11853297
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy.
Liu MT; Hsu JC; Liu WS; Wang AY; Huang WT; Chang TH; Pi CP; Huang CY; Huang CC; Chou PH; Chen TH
Eur J Cancer Care (Engl); 2008 Mar; 17(2):174-81. PubMed ID: 18302655
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant cisplatin and etoposide followed by radical hysterectomy for stage 1B-2B cervical cancer.
Bae JH; Lee SJ; Lee A; Park YG; Bae SN; Park JS; Namkoong SE
Gynecol Oncol; 2008 Dec; 111(3):444-8. PubMed ID: 18829085
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
[TBL] [Abstract][Full Text] [Related]
12. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
[TBL] [Abstract][Full Text] [Related]
13. Regarding a series of IB bulky cervical cancer treated with neoadjuvant chemotherapy (NACT) and radical hysterectomy and pelvic lymphadenectomy.
Bolis G; Villa A; Guarnerio P; Acerboni S; Parazzini F
Gynecol Oncol; 1996 Apr; 61(1):156-8. PubMed ID: 8626108
[No Abstract] [Full Text] [Related]
14. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy.
Lai CH; Hsueh S; Chang TC; Tseng CJ; Huang KG; Chou HH; Chen SM; Chang MF; Shum HC
Gynecol Oncol; 1997 Mar; 64(3):456-62. PubMed ID: 9062150
[TBL] [Abstract][Full Text] [Related]
15. Cervical cancer: combined modality therapy.
Grigsby PW
Cancer J; 2001; 7 Suppl 1():S47-50. PubMed ID: 11504285
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of paclitaxel/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy.
Hosaka M; Watari H; Kato T; Odagiri T; Konno Y; Endo D; Mitamura T; Kikawa S; Suzuki Y; Sakuragi N
J Surg Oncol; 2012 May; 105(6):612-6. PubMed ID: 22065519
[TBL] [Abstract][Full Text] [Related]
17. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
Lee JY; Kim YH; Kim MJ; Kim K; Chung HH; Park NH; Song YS; Kang SB
Arch Gynecol Obstet; 2011 Aug; 284(2):477-82. PubMed ID: 20878172
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant intraarterial infusion chemotherapy in patients with stage IB2-IIIB cervical cancer.
Yamakawa Y; Fujimura M; Hidaka T; Hori S; Saito S
Gynecol Oncol; 2000 May; 77(2):264-70. PubMed ID: 10785476
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of maximally aggressive trimodality therapy in a high-risk subset of early-stage cervical cancer patients.
Elliott KS; Borowsky ME; Malka ES; Scudder SA; Leiserowitz GS; Russell AH
J Reprod Med; 2006 May; 51(5):383-8. PubMed ID: 16779984
[TBL] [Abstract][Full Text] [Related]
20. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.
Takeshima N; Umayahara K; Fujiwara K; Hirai Y; Takizawa K; Hasumi K
Gynecol Oncol; 2006 Nov; 103(2):618-22. PubMed ID: 16777200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
